Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Université´ D'aix-Marseille

UniversitÉ Paris Descartes

Université Paris—sud

Cis Bio International

Institut Jean Paoli & Irène Calmettes

Cisbio Bioassays

Université D'auvergne

Ciscio Bioassays

Inserm (institut National De La Sante Et De La Recherche Medicale)

Jean-Philippe Pin

Daniel Baty

Gérard Mathis

Cyril Goudet

Eric Trinquet

Patrick Chames

Jurriaan Zwier

Francine Acher

Alain Eschalier

Jérôme Busserolles

Damien Nevoltris

Elodie Julie Dupuis

Florence Gaven

Camille S Mailhac

Patrick J M Chames

Julien Jean-Marius Soule

Thomas Fabien Michel Roux

Philippe Rondard

Mélanie Da Silva

Eric Jacques Christian Trinquet

Laurent Prezeau

Etienne Doumazane

Thierry Durroux

Bruno Commare

Sara Cesarini

Isabelle Lemasson

Delphine Rigault

Pauline Scholler

The present invention relates to a single-domain antibody (sdAb) which binds to the G protein alpha, comprising an amino acid sequence consisting of 3 CDR regions (CDR1 to CDR3) and 4 hinge regions (FR1 to FR4) according to the following formula (I): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I) and advantageously having a dissociation constant (Kd), measured in FRET, of less than 100 nM.

Single-domain antibody binding to the G protein alpha

The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Anti-mGluR2 conformational single domain antibodies and uses thereof

The invention relates to hypophosphorous acid derivatives of formula (I) wherein &#x2014;X is H or OH, &#x2014;R represents one or several radicals R-R, identical or different, two of R-Roptionally occupying the same position on the phenyl group, one to four of R-Rbeing H and the others being selected in the group comprising -0-(CH)&#x2014;COOH; &#x2014;S&#x2014;(CH)&#x2014;COOH; &#x2014;NH&#x2014;(CH)&#x2014;COOH; -0-(CH,R')&#x2014;COOH; &#x2014;O&#x2014;(CH)&#x2014;OH; OR&#x2032;, &#x2014;R&#x2032; being a C-Calkyl radical; &#x2014;OH; &#x2014;COOH; halogen, particularly &#x2014;F, &#x2014;CI, &#x2014;Br, &#x2014;I, &#x2014;CF; &#x2014;OCF; &#x2014;N0; &#x2014;CH&#x2550;CH&#x2014;COOH; &#x2014;(CH)&#x2014;COOH; O&#x2014;(CH)&#x2014;P0H; O&#x2014;(CF)&#x2014;P0H; O&#x2014;(CH)&#x2014;S0H; O&#x2014;(CH)&#x2014;CONHOH; O&#x2014;(CH)-tetrazol; O&#x2014;(CH)-hydroxyisoxazol&#x2014;n=1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers. 

Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof

The invention relates to a method for determining whether a test compound binds preferentially to a membrane receptor R1 or to a membrane receptor R2, these receptors being known to be expressed on the surface of the cells in monomeric, homodimeric or heterodimeric form. This method is applied using one or two FRET partner pairs.

Method for determining the binding of a given compound to a membrane receptor

A method for identifying and selecting a compound acting as an allosteric regulator of a GPCR-III is described. A method comparing the activity level of a recombinant GPCR-III (GPCR-III-&#x394;), essentially depleted of the extracellular domain of the corresponding native GPCR-III, in the presence of a given compound, with the activity level of the same GPCR-III-&#x394; is described. A method of identifying positive or negative allosteric regulators of GPCRs-III is described.

Method for selecting allosteric regulators of class III G protein-coupled receptors

Growing community of inventors

Montpellier, France

Jean-Philippe Pin